BeOne Medicines (NASDAQ:ONC) CEO Sells 11,698 Shares of Stock

by · The Cerbat Gem

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) CEO John Oyler sold 11,698 shares of the company’s stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $298.34, for a total value of $3,489,981.32. Following the completion of the transaction, the chief executive officer owned 11,698 shares in the company, valued at $3,489,981.32. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Oyler also recently made the following trade(s):

  • On Monday, July 13th, John Oyler sold 48,520 shares of BeOne Medicines stock. The shares were sold at an average price of $304.35, for a total value of $14,767,062.00.
  • On Tuesday, July 14th, John Oyler sold 145,861 shares of BeOne Medicines stock. The shares were sold at an average price of $305.95, for a total value of $44,626,172.95.
  • On Tuesday, June 23rd, John Oyler sold 3,410 shares of BeOne Medicines stock. The shares were sold at an average price of $273.78, for a total value of $933,589.80.
  • On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The stock was sold at an average price of $265.55, for a total value of $980,676.15.
  • On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The stock was sold at an average price of $257.24, for a total value of $501,360.76.
  • On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The shares were sold at an average price of $270.56, for a total transaction of $1,336,566.40.

BeOne Medicines Trading Up 0.9%

NASDAQ ONC traded up $2.60 during trading hours on Tuesday, reaching $306.56. The company had a trading volume of 446,980 shares, compared to its average volume of 275,519. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. The stock has a market capitalization of $33.64 billion, a P/E ratio of 68.58 and a beta of 0.49. The stock has a 50-day moving average of $290.24 and a 200 day moving average of $308.90. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $253.95 and a 1-year high of $385.22.

BeOne Medicines (NASDAQ:ONC – Get Free Report) last released its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The business had revenue of $1.51 billion for the quarter. As a group, research analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post 5.86 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on ONC. Citizens Jmp restated a “market outperform” rating and issued a $396.00 price target on shares of BeOne Medicines in a research note on Wednesday, July 1st. Barclays dropped their price objective on BeOne Medicines from $409.00 to $403.00 and set an “overweight” rating on the stock in a report on Tuesday. Guggenheim boosted their target price on BeOne Medicines from $410.00 to $420.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Wells Fargo & Company began coverage on BeOne Medicines in a research note on Monday, May 4th. They set an “overweight” rating and a $400.00 target price for the company. Finally, Wall Street Zen downgraded BeOne Medicines from a “strong-buy” rating to a “buy” rating in a report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $390.92.

Read Our Latest Analysis on ONC

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ONC. Bank of America Corp DE acquired a new position in BeOne Medicines during the second quarter worth approximately $67,657,000. Man Group plc acquired a new stake in shares of BeOne Medicines in the second quarter valued at approximately $59,031,000. BNP Paribas Financial Markets purchased a new position in shares of BeOne Medicines during the second quarter worth approximately $38,337,000. First Trust Advisors LP grew its position in shares of BeOne Medicines by 91.9% during the first quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock worth $71,696,000 after acquiring an additional 115,601 shares during the last quarter. Finally, Qube Research & Technologies Ltd purchased a new position in shares of BeOne Medicines during the second quarter worth approximately $26,034,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

About BeOne Medicines

(Get Free Report)

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Recommended Stories